A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Part of paid clinical trials in Oceanside, California.

Sponsor
UCB Biopharma SRL
Study ID
NCT07277660
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Galvokimig — BIOLOGICAL
    Drug: Galvokimig Pharmaceutical form: Solution for injection
  • Placebo — DRUG
    Drug: Placebo Pharmaceutical form: Solution for injection

Study Details

The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

Key Dates

Start date
Dec 29, 2025
Status verified
Jun 2026
Primary completion
May 17, 2027
Completion
Mar 6, 2028

Study Design

Enrollment
160 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Galvokimig Arm 1
    Participants will receive a predefined Galvokimig Dose during Initial Intervention Period. After week 16 participants will continue on the same or a modfied dose.
  • Experimental: Galvokimig Arm 2
    Participants will receive a predefined Galvokimig Dose during Initial Intervention Period. After week 16 participants will continue on the same or a modfied dose.
  • Experimental: Galvokimig Arm 3
    Participants will receive a predefined Galvokimig Dose during Initial Intervention Period. After week 16 participants will continue on the same or a modfied dose.
  • Placebo Comparator: Placebo
    Participants will receive matching placebo during Initial Intervention Period. After week 16 participants will continue on the same or a dose galvokimig.

Primary Outcome Measure

Percentage of participants with Eczema Area and Severity Index (EASI)75 response at Week 16 [ Time Frame: Week 16 ]

Central Contacts

Locations (20)

FacilityCityStateZIPSite coordinators
Atd002 52021OceansideCalifornia92056-
Atd002 52008Santa MonicaCalifornia90404-
Atd002 52013Boca RatonFlorida33486-
Atd002 52007Coral GablesFlorida33134-
Atd002 52003MiamiFlorida33133-
Atd002 52015SavannahGeorgia31419-
Atd002 52017ChicagoIllinois60611-
Atd002 52018WheatonIllinois60189-
Atd002 52012New AlbanyIndiana47150-
Atd002 52014Bowling GreenKentucky42104-
Atd002 52001TroyMichigan48084-
Atd002 52009TroyMichigan48084-
Atd002 52010OmahaNebraska68144-
Atd002 52022New YorkNew York10029-6574-
Atd002 52020The BronxNew York10455-
Atd002 52019PhiladelphiaPennsylvania19114-
Atd002 52005DallasTexas75230-
Atd002 52011FriscoTexas75034-
Atd002 52016FriscoTexas75033-
Atd002 52004Sugar LandTexas77479-

Find similar trials in Oceanside, CA

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Atd002 52021· Oceanside, CAAtd002 52008· Santa Monica, CAAtd002 52013· Boca Raton, FLAtd002 52007· Coral Gables, FLAtd002 52003· Miami, FLAtd002 52015· Savannah, GA

Related Studies